Key Takeaways from AASLD 2024
December 17, 2024, 9AM PT
Liver health experts Dr. Naim Alkhouri and patient advocate Michael Betel share highlights and key insights from the world’s leading forum on liver disease!
Keep up to date with us.
Learn about the latest advances in assessing and managing liver disease, featuring key opinion leaders and subject matter experts.
Liver health experts Dr. Naim Alkhouri and patient advocate Michael Betel share highlights and key insights from the world’s leading forum on liver disease!
Join Key Opinion Leader and renowned endocrinologist Dr. Kenneth Cusi for an informative webinar that will unpack the relationship between diabetes and fatty liver disease.
Listen to expert panel Dr. Stephen Harrison, Dr. Maru/Mary Rinella, and Dr. Mazen Noureddin as they discuss the practical implications of a NASH drug approval.
Find our latest news and company updates. For all media inquiries, contact us at communications@sonicincytes.com.
Ensuring proper use of CPT codes for liver elastography not only facilitates smooth reimbursements but also helps avoid unnecessary claim
VANCOUVER, British Columbia — (BUSINESS WIRE) — Sonic Incytes Medical Corp, a leader in point-of-care ultrasound, proudly announces that the
FATTY LIVER DISEASE Fatty liver disease is the fastest-growing segment of chronic liver disease, with an estimated one in three
Sonic Incytes was recognized as a “Company to Watch” at the 25th Annual LSBC Awards Gala, presented by Farris. This
Discover the latest insights in metabolic health with our exclusive series of videos featuring renowned Key Opinion Leader, Dr. Stephen Harrison. Dive into discussions covering the most recent news and trends related to metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), previously recognized as NAFLD and NASH.
Official versions of the Sonic Incytes and Velacur logos.